Conclusions : C and esartan is superior to losartan in reducing blood pressure .
C and esartan also causes fewer serious adverse events than losartan
Background : C and esartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker ( ARB ) .
Several clinical trials have compared c and esartan with losartan in the management of essential hypertension .
However , systematic assessment of efficacy and safety between c and esartan and losartan is still lacking .
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
This report presents data on the safety and tolerability of losartan potassium ( losartan ) , a selective antagonist of the angiotensin II AT-1 receptor , in approximately 2,900 hypertensive patients treated in double-blind clinical trials . In these studies , headache ( 14.1 % ) , upper respiratory infection ( 6.5 % ) , dizziness ( 14.1 % ) , asthenia/fatigue ( 3.8 % ) , and cough ( 3.1 % ) were the clinical adverse experiences most often reported in patients treated with losartan .  These adverse experiences were also frequently reported in patients receiving placebo : 17.2 % , 5.6 % , 2.4 % , 3.9 % , and 2.6 % , respectively . Dry cough as an adverse event was reported in 8.8 % of patients treated with angiotensin-converting enzyme inhibitors , and in 3.1 % and 2.6 % of patients treated with losartan or placebo , respectively . Only dizziness was considered " drug-related " more often in losartan-treated ( 2.4 % ) than placebo-treated ( 1.3 % ) patients . In controlled clinical trials , losartan was better tolerated than other antihypertensive agents as determined by the incidence of patients reporting any drug-related adverse experiences . Rates of discontinuation due to clinical adverse experiences in patients who received losartan monotherapy or losartan+hydrochlorothiazide were 2.3 % and 2.8 % , respectively , compared with placebo ( 3.7 % ) . No laboratory adverse experiences were unexpected or of clinical importance . First-dose hypotension rarely occurred with losartan or with losartan plus hydrochlorothiazide , and withdrawal effects such as rebound hypertension were not observed in clinical trials . There were no clinical ly important differences in the clinical or laboratory safety profiles in the demographic subgroups for age , gender , or race . In controlled clinical trials , losartan demonstrated an excellent tolerability profile
Conclusions : C and esartan is superior to losartan in reducing blood pressure .
C and esartan also causes fewer serious adverse events than losartan
Background : C and esartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker ( ARB ) .
Several clinical trials have compared c and esartan with losartan in the management of essential hypertension .
However , systematic assessment of efficacy and safety between c and esartan and losartan is still lacking .